Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.41
Bid: 1.41
Ask: 1.43
Change: -0.02 (-1.40%)
Spread: 0.02 (1.418%)
Open: 1.41
High: 1.41
Low: 1.41
Prev. Close: 1.43
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison issues flash on RTW Venture Fund (RTW)

13 Dec 2022 10:01

RNS Number : 5432J
RTW Venture Fund Limited
13 December 2022
 

London, UK, 13 December 2022

 

Edison issues flash on RTW Venture Fund (RTW)

RTW Venture Fund (RTWVF) is managed by global healthcare specialist RTW Investments (RTW). It has announced that on 7 December 2022 portfolio company Prometheus Biosciences (NASDAQ: RXDX, cap $4.9bn) reported positive data on two of its clinical trials. At 31 October 2022, which is the date of RTWVF's last published NAV, Prometheus was its third-largest holding, making up c 7.5% of the fund. This company's share price rose by 165.7% on 7 December and by a further 22.4% on 8 December (despite the announcement of an upsized $500m secondary offering). Prometheus is an example of RTW's long-term, full life cycle investment approach, which supports companies ranging from newco formation to mid-stage venture to pre-initial public offering and public markets.

 

RTWVF, along with other funds managed by RTW, participated in a $130m financing round in Prometheus in November 2020 and then supported the company's IPO in March 2021.

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn www.linkedin.com/company/edison-group-/

Twitter www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABGBDDGGBDGDX
Date   Source Headline
27th Apr 20206:27 pmRNSIssue of Equity
27th Apr 202011:40 amRNSIssue of Equity
27th Apr 20207:00 amRNSAnnouncement of further Share Issuance
24th Apr 20206:27 pmRNSIssue of Equity
23rd Apr 20207:00 amRNSAnnouncement of Share Issuance
22nd Apr 20207:01 amRNSPerformance Allocation Share Distribution Deferral
22nd Apr 20207:00 amRNSAnnual Report and Audited Financial Statements
20th Apr 20207:00 amRNSDirector/PDMR Shareholding
17th Apr 20207:00 amRNSQuarterly Update
15th Apr 20206:22 pmRNSNet Asset Value(s)
9th Apr 20204:22 pmRNSNotice of Annual Report
1st Apr 20206:00 pmRNSSeries B2 Financing in iTeos Therapeutics
1st Apr 20204:00 pmRNSName Change of Administrator and Company Secretary
18th Mar 202012:23 pmRNSDirector/PDMR Shareholding
18th Mar 202011:56 amRNSDirector/PDMR Shareholding
13th Mar 20207:00 amRNSNet Asset Value(s)
2nd Mar 20207:00 amRNSTotal Voting Rights
26th Feb 20207:00 amRNSIssue of Equity
19th Feb 20207:00 amRNSIssue of Equity
17th Feb 20205:10 pmRNSAnnouncement of Share Issuance
14th Feb 20207:00 amRNSNet Asset Value(s)
3rd Feb 20207:00 amRNSTotal Voting Rights
29th Jan 20207:00 amRNSIssue of Equity
27th Jan 20207:00 amRNSIssue of Equity
17th Jan 20204:30 pmRNSIssue of Equity
16th Jan 20207:00 amRNSIssue of Equity
15th Jan 20207:00 amRNSNet Asset Value(s)
23rd Dec 201911:28 amRNSHolding(s) in Company
16th Dec 20195:57 pmRNSNet Asset Value(s)
21st Nov 20193:45 pmRNSRTW leads $100M Financing in Avidity Biosciences
5th Nov 201910:00 amRNSHolding(s) in Company
5th Nov 20199:44 amRNSHolding(s) in Company
1st Nov 20197:00 amRNSTotal Voting Rights
30th Oct 20193:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.